Regulatory Relief to Promote Domestic Production of Critical Medicines

President Donald Trump has issued an executive order aimed at boosting domestic production of critical medicines by streamlining regulatory processes. This action mandates the FDA, EPA, and other agencies to review and eliminate unnecessary barriers, expediting approvals for pharmaceutical manufacturing in the U.S. The initiative could significantly enhance national security by reducing reliance on foreign pharmaceutical imports, though it may face legal challenges regarding environmental and regulatory standards.